On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- First Possible Adverse Reactions from Pfizer Vaccine Reported in Japan
February 22, 2021
- Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
February 22, 2021
- Govt Plans Ticket Barcode Scan for New Vaccination Tracking System
February 18, 2021
- Japan Might Reconsider Vaccine Use for Kids under Age 16 If Data Obtained
February 18, 2021
- Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan
February 18, 2021
- Japan Launches COVID-19 Vaccination Program
February 18, 2021
- MHLW Hints It Might Take 1 Year for Kobayashi Kako to Resume Operations
February 17, 2021
- COVID-19 Vaccine Being Rolled Out for 40,000 Healthcare Workers in Japan
February 17, 2021
- Pregnant Women Not Urged to “Make Efforts” to Get COVID-19 Vaccines
February 16, 2021
- Chugai’s Blood-Based Genomic Profiling Test Now in Line for March OK
February 16, 2021
- PAFSC Minutes for Pfizer Vaccine Review Due Out around Feb. 26
February 16, 2021
- 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
February 16, 2021
- PMDA Review Report: Pfizer Vaccine’s Efficacy for Variants Not Gauged in Clinical Trials, Continued Info Collection Needed
February 16, 2021
- Japan to Start COVID-19 Vaccination on Feb. 17: PM Suga
February 15, 2021
- PMDA to Expand MID-NET Use in Revised Guidelines from April
February 15, 2021
- JCR’s Sakigake Designated Hunter Syndrome Med Up for PAFSC Review on Feb. 25
February 15, 2021
- Pfizer Vaccine Deal Based on “Number of Doses”, Not Vials: Minister
February 15, 2021
- Japan Approves Pfizer’s COVID-19 Vaccine, Rollout Set for Mid Week
February 15, 2021
- Chuikyo OKs Flow of CEA-Based Re-Pricing, New Price Effective 3 Months after Announcements
February 12, 2021
- MHLW Orders Pref. Govts to Strengthen Snap Inspections against Drug Makers after Kobayashi Kako Fiasco
February 12, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…